```html

Zygomatic Infection (Facial Cellulitis)

Overview

Zygomatic infection—also called facial cellulitis of the zygomatic (cheek) region—is an acute bacterial infection of the deep soft‑tissue layers that lie over the cheekbone (the zygoma). It is a type of cellulitis that spreads beneath the skin but above the facial muscles, producing swelling, redness, and pain.

While cellulitis can affect any part of the body, facial involvement is less common than lower‑leg cellulitis. The zygomatic area accounts for roughly 5–10 % of all cellulitis cases in the United States. The condition occurs most often in adults aged 30–60 years, but children and elderly patients can be affected as well.

Because the face houses critical structures (eyes, nose, sinuses, and the cranial cavity), a zygomatic infection can progress quickly and become a medical emergency if not treated promptly.

Symptoms

The clinical picture may vary, but most patients present with the following features:

• Redness (erythema) – a sharply demarcated area of pink‑to‑purple skin over the cheekbone.
• Swelling (edema) – often “puffy” and may feel tense to the touch.
• Pain or tenderness – worsens with facial movement, chewing, or pressure.
• Warmth – the infected region feels hotter than surrounding tissue.
• Fever – low‑grade (37.5–38.5 °C) in mild cases, higher (>39 °C) if the infection spreads.
• Headache – may be localized to the affected side.
• Difficulty opening the mouth (trismus) – especially if the infection spreads to the masseter muscle.
• Dental pain – if the infection originated from a dental abscess.
• Skin changes – such as a “streaking” pattern indicating lymphatic spread (lymphangitis).
• Systemic signs – chills, fatigue, and malaise.

Causes and Risk Factors

Primary Causes

Facial cellulitis is usually polymicrobial, but two groups dominate:

• Staphylococcus aureus (including methicillin‑resistant strains – MRSA).
• Streptococcus pyogenes (Group A Streptococcus).

These organisms enter the subcutaneous tissue through a break in the skin or a mucosal surface.

Common Entry Points

• Dental infections (periodontal disease, periapical abscess).
• Skin trauma – cuts, abrasions, insect bites, or surgical incisions.
• Upper‑respiratory infections – sinusitis or otitis media that breach the facial planes.
• Facial cosmetic procedures (fillers, implants) if aseptic technique is compromised.

Risk Factors

• Diabetes mellitus – impairs neutrophil function (CDC, 2022).
• Immunosuppression – HIV, chemotherapy, steroids.
• Chronic skin conditions – eczema, dermatitis.
• Poor oral hygiene and untreated dental disease.
• Obesity – associated with impaired lymphatic drainage.
• Recent facial surgery or trauma.

Diagnosis

Diagnosis is primarily clinical, but several investigations help confirm the infection, rule out mimickers, and assess severity.

Physical Examination

• Inspection for erythema, edema, and “streaking.”
• Palpation for warmth, tenderness, and fluctuance (suggesting an abscess).
• Assessment of facial nerve function and ocular involvement.

Laboratory Tests

• Complete blood count (CBC) – leukocytosis (>12 × 10⁹/L) in most cases.
• CRP & ESR – markers of inflammation, useful for monitoring response.
• Blood cultures – indicated if fever >39 °C or signs of sepsis.

Microbiological Sampling

If an abscess is present, needle aspiration can obtain pus for Gram stain and culture, guiding targeted antibiotic therapy.

Imaging

• Ultrasound – bedside tool to differentiate cellulitis from an abscess.
• Contrast‑enhanced CT scan – gold standard for deep facial infections, evaluates spread to the orbit, sinuses, or intracranial space.
• MRI – reserved for suspected osteomyelitis or cavernous sinus thrombosis.

Treatment Options

Management combines empiric antibiotics, possible procedural drainage, and supportive care.

Antibiotic Therapy

Guidelines from the Infectious Diseases Society of America (IDSA) recommend starting broad‑spectrum coverage within 1 hour of diagnosis.

Empiric Regimen	Typical Dose	Coverage
Clindamycin 600 mg IV q6h	4 days IV → PO	MRSA + anaerobes
Cefazolin 2 g IV q8h	5–7 days IV	MSSA, Streptococcus
Vancomycin (adjusted for renal function) + Piperacillin‑tazobactam	IV	Broad‑spectrum + MRSA

Switch to oral agents (e.g., amoxicillin‑clavulanate, doxycycline) once there is clinical improvement and the patient can tolerate oral intake.

Procedural Intervention

• Incision & drainage (I&D) – indicated if a fluctuant abscess is present or if imaging shows a collection >2 cm.
• Dental extraction or root canal – if the source is odontogenic.
• Endoscopic sinus surgery – for concurrent sinusitis unresponsive to medical therapy.

Adjunctive Measures

• Analgesia – acetaminophen or ibuprofen for pain and fever.
• Warm compresses – 15 minutes, 3–4 times daily to improve circulation.
• Elevation of the head – reduces edema.
• Hydration – supports immune function.

Duration of Therapy

Most uncomplicated cases resolve after 7–10 days of antibiotics. Severe or deep infections may require 2–3 weeks, guided by clinical response and inflammatory markers.

Living with Zygomatic Infection (Facial Cellulitis)

Daily Management Tips

• Follow the medication schedule exactly; missed doses increase resistance risk.
• Maintain oral hygiene – gentle brushing, antiseptic mouthwash (e.g., chlorhexidine) if dental origin.
• Apply warm compresses as described to reduce discomfort.
• Track symptoms—note any increase in swelling, pain, or fever.
• Rest and nutrition – lean protein, fruits/vegetables rich in vitamin C and zinc.
• Avoid smoking and alcohol – both impair wound healing.

When to Contact Your Provider

Call your clinician if you notice worsening redness, new pus drainage, rising temperature after 48 hours of therapy, or any new neurological signs (double vision, facial droop).

Prevention

• Good oral health: brush twice daily, floss, regular dental check‑ups.
• Prompt wound care: clean cuts with soap and water, apply sterile bandage, seek care if infection is suspected.
• Manage chronic diseases: keep blood glucose and blood pressure under control.
• Vaccinations: influenza and pneumococcal vaccines reduce secondary bacterial infections.
• Avoid sharing personal items (razors, towels) that can transmit MRSA.
• Hand hygiene: wash hands for at least 20 seconds before touching the face.

Complications

If left untreated or inadequately treated, zygomatic cellulitis can lead to serious sequelae:

• Orbital cellulitis – infection spreads to the eye socket, causing vision loss.
• Cavernous sinus thrombosis – a life‑threatening clot in a deep skull venous structure.
• Osteomyelitis of the zygomatic bone – requires prolonged antibiotics and possible surgical debridement.
• Abscess formation – may rupture, necessitating surgical drainage.
• Sepsis – systemic inflammatory response with organ dysfunction.
• Scarring or facial disfigurement – rare but possible with severe inflammation.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Cellulitis: Symptoms, Causes, and Treatment. Updated 2022.
• Mayo Clinic. Cellulitis. Accessed May 2026.
• Infectious Diseases Society of America. Clinical Practice Guidelines for Skin and Soft Tissue Infections. 2023.
• National Institutes of Health. Management of Facial Cellulitis. JAMA Dermatol. 2020.
• Cleveland Clinic. Cellulitis Overview. Updated 2021.
• World Health Organization. Antimicrobial resistance. 2023.

```